For more than two decades, women considering hormone replacement therapy have faced conflicting information. Some have been told that hormone therapy offers meaningful relief from hot flashes, night sweats, and other disruptive menopause symptoms. Others have avoided it entirely because of concerns about breast cancer, heart disease, or long-term complications, often based on headlines from years ago rather than current evidence.
In February 2026, the U.S. Food and Drug Administration approved significant changes to the safety labeling of menopausal hormone therapy products, removing statements about cardiovascular disease, breast cancer, and probable dementia from the most prominent warnings on an initial group of six medications. The decision represents a real shift in how certain risks are communicated, particularly for women who begin treatment during or shortly after menopause. It does not mean hormone therapy is risk-free or appropriate for every woman, and understanding the difference is the point of this article.
At Enovative Wellness in Phoenix, we believe hormone care should begin with a clear understanding of each woman’s symptoms, medical history, and overall health. The FDA’s updated labeling creates an opportunity to have that conversation with greater clarity than has been possible for a long time.
Understanding the FDA’s 2026 Hormone Therapy Label Changes
On November 10, 2025, the FDA announced its intention to revise certain safety warnings on menopausal hormone therapy. After reviewing the scientific literature, the agency approved updated labeling for six hormone therapy products on February 12, 2026. The central change removed statements about cardiovascular disease, breast cancer, and probable dementia from the boxed warning, which is the FDA’s most prominent safety notice. The initial approvals covered products representing systemic estrogen therapy, combined estrogen-progestogen therapy, progestogen used alongside estrogen, and local vaginal estrogen. Other manufacturers had submitted revisions, but those submissions did not automatically change the labeling of every hormone product on the market.
Boxed warnings strongly influence how both patients and clinicians perceive a medication, so the change matters. At the same time, removing a statement from a boxed warning is not the same as concluding that the associated risk no longer exists. Individual product warnings, contraindications, and prescribing information remain in place and remain essential. The most useful way to read the FDA’s decision is as an invitation to revisit the evidence and have an informed medical discussion, not as a blanket recommendation to begin treatment.
Why Hormone Replacement Therapy Became Controversial
Much of the concern surrounding HRT traces back to the Women’s Health Initiative, a large research program whose 2002 findings raised questions about the relationship between certain hormone regimens and cardiovascular disease, breast cancer, stroke, and blood clots. Hormone therapy use fell sharply afterward. Many women stopped treatment, and many more never considered it despite symptoms that affected their daily lives.
As researchers examined the data more closely, important context emerged. The average WHI participant was about 63 years old, considerably older than women first entering menopause, and the study used specific hormone formulations that should not be treated as interchangeable with every estrogen or progesterone product available today. Later research clarified that the balance of benefits and risks depends on when treatment begins, which hormones are used, how they are delivered, and whether a woman has existing medical conditions. The original concerns were not unfounded; the lesson is that results from one patient population cannot be applied equally to every woman. The FDA’s labeling changes reflect that evolving understanding.
Why Age and Timing Matter When Starting Hormone Therapy
One of the most important factors in HRT decisions is the relationship between a woman’s age, the time since menopause, and the potential risks of treatment. According to The Menopause Society, the balance of benefits and risks is generally favorable for otherwise healthy women who begin systemic hormone therapy before age 60 or within 10 years of menopause onset, provided they have no contraindications. For women who begin later, the balance becomes less favorable because absolute risks involving cardiovascular disease, stroke, blood clots, and dementia increase with age.
Consider a hypothetical 52-year-old who recently entered menopause and is dealing with frequent night sweats, interrupted sleep, and hot flashes that interfere with her work. With no medical conditions that would rule out treatment, her provider may reasonably determine that systemic hormone therapy is an option worth discussing. Now consider a 68-year-old who entered menopause nearly two decades ago and has a history of blood clots. Even with similar symptoms, starting systemic therapy involves very different safety considerations and may not be appropriate. Neither example describes an actual patient, but together they illustrate why the decision is never about symptom severity alone. Age, time since menopause, cardiovascular health, medical history, and formulation all shape clinical judgment, and hormone therapy should not be prescribed solely to prevent aging or cardiovascular disease.
The Potential Benefits of Hormone Replacement Therapy
Menopause occurs as ovarian hormone production declines, particularly estrogen, and those changes can affect multiple systems throughout the body for years. Systemic hormone therapy remains the most effective established treatment for moderate to severe vasomotor symptoms, the clinical term for hot flashes and night sweats. These are more than occasional discomfort: frequent nighttime sweating interrupts sleep, contributes to daytime fatigue, and affects concentration, mood, and quality of life. By reducing these symptoms, hormone therapy may also improve sleep for women whose sleep problems are primarily driven by them, though not every midlife sleep or fatigue complaint is caused by declining estrogen.
Estrogen also plays a central role in maintaining bone density. After menopause, falling estrogen accelerates bone loss and raises the risk of osteoporosis and fractures, and certain hormone therapy products are approved to help prevent postmenopausal osteoporosis. Hormone therapy can also relieve vaginal dryness, discomfort during intercourse, and related urinary symptoms caused by changes in estrogen-sensitive tissue; in those cases, local vaginal treatment is often more appropriate than systemic therapy. The benefits are meaningful, but treatment should address an identifiable clinical need. Hormones are not a universal solution for weight gain, fatigue, or cognitive changes that may have several contributing causes.
Hormone Therapy Risks That Still Require Individual Evaluation
The updated labeling does not eliminate the need to discuss risk. Systemic estrogen and estrogen-progestogen treatments carry risks that depend on the medication, dose, route of administration, duration, and individual health history. Oral estrogen, for example, can increase the risk of venous thromboembolism, which refers to blood clots in the deep veins or lungs. Research suggests that transdermal estrogen delivered through a patch, gel, or spray may carry a lower clotting risk, although individual circumstances still matter.
Breast cancer risk also requires careful consideration. The evidence differs between estrogen-only therapy and certain combined regimens, particularly with longer use, and removing breast cancer language from a boxed warning is not proof that every systemic therapy carries identical or negligible risk. Women who have a uterus generally need adequate progesterone or another progestogen alongside systemic estrogen, because unopposed estrogen can stimulate the uterine lining and increase endometrial cancer risk. Women with a history of certain cancers, blood clots, stroke, cardiovascular events, active liver disease, or unexplained vaginal bleeding may have contraindications to systemic therapy altogether. These considerations are why a treatment decision cannot rest on symptoms or hormone levels alone.
Systemic Hormone Therapy and Local Vaginal Estrogen Are Not the Same Decision
Systemic hormone therapy delivers hormones into the bloodstream so they can act on tissues throughout the body, which is what makes it effective for hot flashes and night sweats. Local vaginal estrogen primarily targets vaginal and nearby urinary tissue, and low-dose preparations produce substantially less systemic exposure. For a woman whose main concerns are vaginal dryness, painful intercourse, or certain urinary symptoms, local treatment may provide meaningful relief without the exposure or considerations that come with systemic therapy. The FDA’s 2026 changes included products from both categories, but the right choice still depends on which symptoms a woman is actually trying to address and on the safety information for the specific product.
Bioidentical Hormone Replacement Therapy and the FDA Changes
The FDA’s announcement naturally raises questions about bioidentical hormone replacement therapy, often called BHRT. Bioidentical hormones have the same molecular structure as those the body produces, and they are available in two forms: FDA-approved medications containing bioidentical estradiol and micronized progesterone, and custom-compounded preparations made by a compounding pharmacy to an individual prescription. FDA-approved products go through regulatory review for safety, effectiveness, and manufacturing consistency. Compounded preparations are made to order, which allows for individualized dosing and alternative delivery forms but means they do not go through the same premarket approval process. ACOG’s clinical guidance discusses that distinction in detail.
Neither form is automatically safer or more effective than the other, and the word bioidentical on its own does not guarantee a better outcome. An FDA-approved product may be the right fit for one woman, while another may need a compounded formulation because of an ingredient intolerance, a dosing requirement, or a delivery method that is not available commercially. The right formulation depends on the individual, and a qualified provider can explain when each makes sense and what to expect from it. The FDA’s labeling changes do not alter that calculus in either direction.
Personalized Hormone Care Requires More Than a Single Lab Result
Hormone levels fluctuate considerably during perimenopause. Estrogen and progesterone do not decline on a predictable schedule, and a woman may have significant hot flashes, disrupted sleep, or cycle changes even when a single blood test falls within the laboratory reference range. For many women over 45 with typical symptoms, medical history and symptom patterns are more informative than routine hormone testing alone. Testing becomes more valuable when symptoms suggest another condition, menopause begins unusually early, or the diagnosis remains unclear.
This is where a broader evaluation matters. At Enovative Wellness, our approach to women’s hormone health considers how symptoms interact with sleep, thyroid function, metabolism, nutrition, stress, and cardiovascular risk. A woman with persistent fatigue and poor concentration may assume declining estrogen explains everything, when thyroid dysfunction, iron deficiency, sleep apnea, or a medication effect may be contributing, which is one reason standard labs can look normal while a patient still feels unwell. Hormone therapy may relieve menopausal symptoms without touching those other issues, so identifying them first leads to better decisions. Under the guidance of Dr. Greg Jones, NMD, ABAAHP, our naturopathic physicians use this root cause approach to understand the complete health picture before recommending treatment.
Making an Informed Decision About Hormone Replacement Therapy
The updated labeling gives women a reason to reconsider hormone therapy based on current evidence rather than on information they encountered years ago. A thoughtful consultation starts by identifying which symptoms are most disruptive and whether hormone therapy is likely to address them. Medical history, current medications, blood pressure, cardiovascular risk, breast health, and family history then inform whether systemic or local treatment is appropriate and which formulation best fits. If therapy is prescribed, follow-up matters: treatment should be reassessed periodically to confirm symptoms are improving, side effects have not emerged, and the benefits continue to outweigh the risks.
Declining hormone therapy does not mean living with disruptive symptoms. Evidence-based nonhormonal options exist for several menopause concerns, and the most appropriate path depends on the individual. The goal of personalized hormone care is not to recommend HRT for women across the board; it is to help each woman understand her symptoms, weigh her options, and make an informed choice about her long-term health.
Frequently Asked Questions About the FDA’s Hormone Therapy Changes
Does the FDA now consider hormone replacement therapy safe?
The labeling changes support a more individualized evaluation of hormone therapy, but they do not establish that treatment is safe for everyone. Age, medical history, symptoms, and risk factors should be reviewed with a qualified healthcare provider before beginning HRT.
Does removing the breast cancer boxed warning mean HRT cannot increase breast cancer risk?
No. Breast cancer risk remains an important consideration, particularly for certain systemic estrogen-progestogen regimens used over longer periods. Removing language from a boxed warning changes how the risk is communicated, not whether it exists.
Can women begin hormone therapy after age 60?
Hormone therapy may be considered in selected women over 60, but starting systemic treatment later generally involves less favorable risk considerations. Some women also continue treatment beyond 60 after an individualized review. Age alone should not replace a comprehensive medical assessment.
Are bioidentical hormones safer than conventional hormone therapy?
Not automatically. Several FDA-approved hormone therapies already contain bioidentical estradiol or progesterone, and compounded products have not been shown to be inherently safer. The specific medication, dose, delivery method, and clinical evidence matter more than the term itself.
Do women need blood tests before starting hormone replacement therapy?
Not always. For many women over 45 with typical menopausal symptoms, clinical history guides the evaluation. Testing becomes more useful when symptoms are unusual, menopause begins early, or another condition such as thyroid dysfunction is suspected.
A More Informed Approach to Women’s Hormone Health
The FDA’s 2026 labeling changes are an important development in how the benefits and risks of menopause treatment are communicated. For many otherwise healthy women with disruptive symptoms, appropriately selected hormone therapy may provide real relief and a better quality of life. For others, medical history, risk factors, or personal preference may point toward a different approach. Hormone replacement therapy is neither universally dangerous nor universally beneficial, and understanding the evidence, the factors that influence safety, and the broader causes of symptoms is what makes an informed decision possible.
If you are experiencing hot flashes, night sweats, sleep disruption, or other symptoms of perimenopause or menopause, you deserve care that takes those concerns seriously and evaluates them in the context of your whole health. Dr. Greg Jones and the Enovative Wellness team provide individualized hormone health evaluations for women in Phoenix, Scottsdale, Paradise Valley, and surrounding Arizona communities. Schedule a consultation to explore whether hormone replacement therapy, bioidentical HRT, or another evidence-informed option is right for you.
Call us at (602) 614-9905 or visit www.EnovativeWellness.com to learn more.
